Literature DB >> 34252300

Combined High-Dose Caspofungin and Liposomal Amphotericin B for Treatment of Azole-Resistant Cerebral Aspergillosis.

A Pouvaret1, A Duréault1, D Garcia-Hermoso2, A Serris1, J F Cohen1, R Guery1, F Lanternier1,2, O Lortholary1,2.   

Abstract

Entities:  

Keywords:  azole resistance; central nervous system; invasive aspergillosis

Mesh：

Substances：

Year:  2021        PMID： 34252300      PMCID： PMC8448151          DOI： 10.1128/AAC.00474-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients.

Authors:  Agustin Resendiz-Sharpe; Toine Mercier; Pieter P A Lestrade; Martha T van der Beek; Peter A von dem Borne; Jan J Cornelissen; Elizabeth De Kort; Bart J A Rijnders; Alexander F A D Schauwvlieghe; Paul E Verweij; Johan Maertens; Katrien Lagrou
Journal:  J Antimicrob Chemother       Date:  2019-09-01       Impact factor: 5.790

2.  Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Improved outcome in central nervous system aspergillosis, using voriconazole treatment.

Authors:  Stefan Schwartz; Markus Ruhnke; Patricia Ribaud; Lawrence Corey; Timothy Driscoll; Oliver A Cornely; Ulrich Schuler; Irja Lutsar; Peter Troke; Eckhard Thiel
Journal:  Blood       Date:  2005-07-05       Impact factor: 22.113

4.  Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Authors:  A J Ullmann; J M Aguado; S Arikan-Akdagli; D W Denning; A H Groll; K Lagrou; C Lass-Flörl; R E Lewis; P Munoz; P E Verweij; A Warris; F Ader; M Akova; M C Arendrup; R A Barnes; C Beigelman-Aubry; S Blot; E Bouza; R J M Brüggemann; D Buchheidt; J Cadranel; E Castagnola; A Chakrabarti; M Cuenca-Estrella; G Dimopoulos; J Fortun; J-P Gangneux; J Garbino; W J Heinz; R Herbrecht; C P Heussel; C C Kibbler; N Klimko; B J Kullberg; C Lange; T Lehrnbecher; J Löffler; O Lortholary; J Maertens; O Marchetti; J F Meis; L Pagano; P Ribaud; M Richardson; E Roilides; M Ruhnke; M Sanguinetti; D C Sheppard; J Sinkó; A Skiada; M J G T Vehreschild; C Viscoli; O A Cornely
Journal:  Clin Microbiol Infect       Date:  2018-03-12       Impact factor: 8.067

5.  Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.

Authors:  Stefan Schwartz; Markus Ruhnke; Patricia Ribaud; Elizabeth Reed; Peter Troke; Eckhard Thiel
Journal:  Mycoses       Date:  2007-05       Impact factor: 4.377

6.  International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.

Authors:  Paul E Verweij; Michelle Ananda-Rajah; David Andes; Maiken C Arendrup; Roger J Brüggemann; Anuradha Chowdhary; Oliver A Cornely; David W Denning; Andreas H Groll; Koichi Izumikawa; Bart Jan Kullberg; Katrien Lagrou; Johan Maertens; Jacques F Meis; Pippa Newton; Iain Page; Seyedmojtaba Seyedmousavi; Donald C Sheppard; Claudio Viscoli; Adilia Warris; J Peter Donnelly
Journal:  Drug Resist Updat       Date:  2015-08-07       Impact factor: 18.500

7.  Azole-resistant central nervous system aspergillosis.

Authors:  Jan W M van der Linden; Rogier R Jansen; Dorine Bresters; Caroline E Visser; Suzanne E Geerlings; Ed J Kuijper; Willem J G Melchers; Paul E Verweij
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

8.  First Detection of TR34 L98H and TR46 Y121F T289A Cyp51 Mutations in Aspergillus fumigatus Isolates in the United States.

Authors:  Nathan P Wiederhold; Veronica Garcia Gil; Felipe Gutierrez; Jonathan R Lindner; Mohammad T Albataineh; Dora I McCarthy; Carmita Sanders; Hongxin Fan; Annette W Fothergill; Deanna A Sutton
Journal:  J Clin Microbiol       Date:  2015-10-21       Impact factor: 5.948
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.